Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Abstract

Liver fibrosis is critical for liver-related outcomes and mortality in chronic liver disease, irrespective of etiology, including nonalcoholic fatty liver disease (NAFLD). NAFLD has been viewed as an independent correlate of cardiovascular risk. This review article briefly describes the cellular and molecular pathomechanisms underlying hepatic fibrosis. We then address noninvasive assessment of liver fibrosis. Finally, we discuss published evidence supporting fibrosis biomarkers’ role in assessing cardiovascular risk among patients with NAFLD. While histological assessment is the diagnostic standard of hepatic fibrosis, we specifically address noninvasive techniques, including equations based on anthropometric parameters, laboratory indices, and elastometry obtained with imaging techniques. The former group includes AST: ALT ratio, the Forns Index, the AST-to-platelet ratio index score, BARD (BMI, AAR, Diabetes) score, the fibrosis-4 index (FIB-4), the NAFLD fibrosis score, the gamma-glutamyl transferase-to-platelet ratio, and the Hepamet fibrosis score. The latter comprises elastographic techniques associated with ultrasonography or magnetic resonance. Our literature review identified numerous studies demonstrating that biomarkers of fibrosis (the most common being FIB-4) and elastographic techniques predict overall mortality and major cardiovascular events among NAFLD patients. The mechanisms accounting for this association are briefly reviewed. In addition to assessing hepatic fibrosis at baseline, during follow-up, and after therapeutic interventions in NAFLD patients, noninvasive assessment of hepatic fibrosis may predict cardiovascular events and overall mortality in these patients.

Keywords

Biomarkers / elastometry / fibroscan / ultrasound / biopsy / cardiovascular risk / natural course / steatohepatitis

References

[1] Parola M.Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.Mol Aspects Med2019;65:37-55

[2] Lambrecht J,Tacke F.Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis.Expert Opin Pharmacother2020;21:1637-50

[3] Friedman SL.Hepatic fibrosis 2022: Unmet needs and a blueprint for the future.Hepatology2022;75:473-88

[4] Gordon SC,Parker E,Ozbay AB.Health care use and costs among patients with nonalcoholic steatohepatitis with advanced fibrosis using the fibrosis-4 score.Hepatol Commun2020;4:998-1011 PMCID:PMC7327220

[5] Tacke F.Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.Ann Transl Med2021;9:729 PMCID:PMC8106094

[6] Friedman SL,Rinella M.Mechanisms of NAFLD development and therapeutic strategies.Nat Med2018;24:908-22 PMCID:PMC6553468

[7] Tsochatzis EA,Burroughs AK.Liver cirrhosis.Lancet2014;383:1749-61

[8] Dulai PS,Patel J.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology2017;65:1557-65

[9] Sanyal AJ,Clark J.Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med2021;385:1559-69 PMCID:PMC8881985

[10] Loomba R,Shulman GI.Mechanisms and disease consequences of nonalcoholic fatty liver disease.Cell2021;184:2537-64

[11] Vilar-Gomez E,Wai-Sun Wong V.Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.Gastroenterology2018;155:443-457.e17

[12] Mantovani A,Petracca G.Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021;6:903-13

[13] Sumida Y,Itoh Y.Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.World J Gastroenterol2014;20:475-85 PMCID:PMC3923022

[14] Lonardo A.Perspectives of nonalcoholic fatty liver disease research: a personal point of view.Explor Med2020;1:85-107

[15] Wang FD,Chen EQ.Molecular mechanisms and potential new therapeutic drugs for liver fibrosis.Front Pharmacol2022;13:787748 PMCID:PMC8874120

[16] Qu W,Cai J.Liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies.Front Med (Lausanne)2021;8:761538 PMCID:PMC8568774

[17] Bitto N,La Mura V.Coagulation, microenvironment and liver fibrosis.Cells2018;7:85 PMCID:PMC6115868

[18] Ballestri S,Fontana MC.Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review.Adv Ther2020;37:1910-32 PMCID:PMC7467481

[19] Davis JPE.Healing gone wrong: convergence of hemostatic pathways and liver fibrosis?.Clin Sci (Lond)2020;134:2189-201

[20] Mahmoud NI,Salehc IG,Abdel-Bakky MS.Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.Life Sci2019;231:116522

[21] Czajka P,Nowak A.Antiplatelet drugs and liver fibrosis.Platelets2022;33:219-28

[22] Rahman SR,Grove JI,Pun KT.Integrins as a drug target in liver fibrosis.Liver Int2022;42:507-21

[23] Dwyer BJ,Brennan PN.Cell therapy for advanced liver diseases: repair or rebuild.J Hepatol2021;74:185-99

[24] Wang S.Hepatic fibrosis: a convergent response to liver injury that is reversible.J Hepatol2020;73:210-1

[25] Aminian A,Wilson R.Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.J Am Med Assoc2021;326:2031-42

[26] Chew NWS,Muthiah MD.Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease.Curr Atheroscler Rep2022;24:515-32

[27] Yang YM,Matsuda M.Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model.Arch Pharm Res2021;44:230-40 PMCID:PMC8407017

[28] Pritchard MT.Identifying novel targets for treatment of liver fibrosis: what can we learn from injured tissues which heal without a scar?.Curr Drug Targets2015;16:1332-46] PMCID:PMC4838187

[29] Andreichenko IN,Fokin AV.4-methylumbelliferone prevents liver fibrosis by affecting hyaluronan deposition, fstl1 expression and cell localization.Int J Mol Sci2019;20:6301 PMCID:PMC6941058

[30] Weiz G,Malvicini M.Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma.Liver Int2022;42:444-57

[31] Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary.Prescrire Int2010;19:38

[32] Lai M.Liver fibrosis determination.Gastroenterol Clin North Am2019;48:281-9

[33] Vilar-Gomez E.Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.J Hepatol2018;68:305-15

[34] Boyle M,Schattenberg JM.Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.JHEP Rep2019;1:188-98 PMCID:PMC7001575

[35] Anstee QM,Loomba R.Impact of non-invasive biomarkers on hepatology practice: past, present and future.J Hepatol2022;76:1362-78

[36] Williams AL.Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis relationship to cirrhosis.Gastroenterology1988;95:734-9

[37] Forns X,Llovet JM.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology2002;36:986-92

[38] Wai CT,Fontana RJ.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology2003;38:518-26

[39] Harrison SA,Arnold HL,Neuschwander-Tetri BA.Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.Gut2008;57:1441-7

[40] Sterling RK,Clumeck N.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.Hepatology2006;43:1317-25

[41] Angulo P,Marchesini G.The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology2007;45:846-54

[42] McPherson S,Dufour JF.Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.Am J Gastroenterol2017;112:740-51 PMCID:PMC5418560

[43] Lemoine M,Nayagam S.The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.Gut2016;65:1369-76

[44] Ampuero J,Aller R.HEPAmet RegistryDevelopment and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis.Clin Gastroenterol Hepatol2020;18:216-225.e5

[45] Ballestri S,Baldelli E.Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.Diagnostics (Basel)2021;11:98 PMCID:PMC7827076

[46] Brandman D,McPherson S.Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).Aliment Pharmacol Ther2022;55:1441-51

[47] Sun W,Li N.Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: a meta-analysis study.Hepatol Res2016;46:862-70

[48] Boursier J,Costentin C.Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications.Clin Gastroenterol Hepatol2022:S1542-3565(22)00248

[49] Petta S,Bugianesi E.The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.Liver Int2015;35:1566-73

[50] Jafarov F,Bakir A,Yilmaz Y.The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study.Eur J Gastroenterol Hepatol2020;32:642-9

[51] Newsome PN,Deeks JJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580

[52] Eddowes PJ,Allison M.Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology2019;156:1717-30

[53] Oeda S,Imajo K.Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: comparison between M and XL probes.Hepatol Res2020;50:831-9

[54] Kim BK,Imajo K.Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.J Hepatol2022;77:1482-90

[55] Ng CH,Hui Lim GE.Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2022:S1542-3565(22)00439

[56] Reddy YK,Jiang Y.Natural history of non-alcoholic fatty liver disease: a study with paired liver biopsies.J Clin Exp Hepatol2020;10:245-54 PMCID:PMC7212293

[57] Perazzo H,Ngo Y.Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.Aliment Pharmacol Ther2014;40:1081-93

[58] Kim D,Kim HJ.Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.Hepatology2013;57:1357-65 PMCID:PMC3622816

[59] Song DS,Kang SG,Yang JM.Noninvasive serum fibrosis markers are associated with coronary artery calcification in patients with nonalcoholic fatty liver disease.Gut Liver2019;13:658-68 PMCID:PMC6860032

[60] Schonmann Y,Bentov I.Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population.Dig Liver Dis2021;53:79-85

[61] Han E,Lee JS.Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease.Gut Liver2022;16:786-97 PMCID:PMC9474484

[62] Chen Q,Li D.Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease.Atherosclerosis2020;299:45-52

[63] Baratta F,Angelico F.Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study.Clin Gastroenterol Hepatol2020;18:2324-2331.e4

[64] Lee J,Cho YK.Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease.Sci Rep2020;10:18323 PMCID:PMC7591518

[65] Liu HH,Jin JL.Liver fibrosis scoring systems as novel tools for predicting cardiovascular outcomes in patients following elective percutaneous coronary intervention.J Am Heart Assoc2021;10:e018869 PMCID:PMC7955446

[66] Peters AE,Ayers C.Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT.ESC Heart Fail2021;8:842-8 PMCID:PMC8006722

[67] Parikh NS,VanWagner LB,Zakai NA.Liver fibrosis is associated with ischemic stroke risk in women but not men: the REGARDS study.J Stroke Cerebrovasc Dis2021;30:105788

[68] Oh TJ,Moon JH,Cho NH.Liver fibrosis indices for the prediction of mortality in korean subjects: a 16-year prospective cohort study.J Endocr Soc2021;5:bvab123 PMCID:PMC8358988

[69] Delgado GE,Moissl AP.Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.Am J Physiol Gastrointest Liver Physiol2021;321:G252-61

[70] Tamaki N,Takahashi Y.Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease.J Gastroenterol Hepatol2021;36:2960-6

[71] Akuta N,Arase Y.PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD.BMC Gastroenterol2021;21:434 PMCID:PMC8603578

[72] Jin JL,Cao YX.Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease.Hepatol Int2021;15:413-23

[73] Zupo R,De Nucci S.Liver fibrosis and 8-year all-cause mortality trajectories in the aging cohort of the salus in apulia study.Biomedicines2021;9:1617 PMCID:PMC8615636

[74] Zupo R,Donghia R.Liver frailty and all-cause mortality in the older participants of the Salus in Apulia study.Geroscience2022;44:835-45 PMCID:PMC9135911

[75] Vieira Barbosa J,Frick A.Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease.Am J Gastroenterol2022;117:453-61

[76] Ferraioli G,Castera L.Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations.Ultrasound Med Biol2018;44:2419-40

[77] Ballestri S,Lugari S,Francica G.A critical appraisal of the use of ultrasound in hepatic steatosis.Expert Rev Gastroenterol Hepatol2019;13:667-81

[78] Ajmera V.Imaging biomarkers of NAFLD, NASH, and fibrosis.Mol Metab2021;50:101167 PMCID:PMC8324681

[79] Lee MS,Joo SK,Lee DH.Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease.PLoS One2017;12:e0188321

[80] Honda Y,Imajo K.Elastography techniques for the assessment of liver fibrosis in non-alcoholic fatty liver disease.Int J Mol Sci2020;21:4039 PMCID:PMC7313067

[81] Conti CB,Fraquelli M,Massironi S.Ultrasound elastographic techniques in focal liver lesions.World J Gastroenterol2016;22:2647-56 PMCID:PMC4777989

[82] Liu H,Hong R,Li F.Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis.PLoS One2015;10:e0127782

[83] Cassinotto C,de Lédinghen V.Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.Hepatology2016;63:1817-27

[84] Jiang W,Teng H.Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis.BMJ Open2018;8:e021787 PMCID:PMC6112406

[85] Herrmann E,Cassinotto C.Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis.Hepatology2018;67:260-72 PMCID:PMC5765493

[86] Castera L,Loomba R.Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease.Gastroenterology2019;156:1264-1281.e4 PMCID:PMC7505052

[87] Selvaraj EA,Jayaswal ANA.Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis.J Hepatol2021;75:770-85

[88] Petta S,Bugianesi E.Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.J Hepatol2018;69:878-85

[89] Berzigotti A,Bota S,Dietrich CF.Novel ultrasound-based methods to assess liver disease: the game has just begun.Dig Liver Dis2018;50:107-12

[90] Park CC,Hernandez C.Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease.Gastroenterology2017;152:598-607.e2 PMCID:PMC5285304

[91] Lee YS,Yi HS.MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.Hepatol Int2022;16:316-24

[92] Polyzos SA,Tsochatzis EA.Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.Aliment Pharmacol Ther2021;54:1013-25

[93] Veracruz N,Saab S.The association between nonalcoholic fatty liver disease and risk of cardiovascular disease, stroke, and extrahepatic cancers.J Clin Exp Hepatol2021;11:45-81 PMCID:PMC7897860

[94] Friedrich-Rust M,Maier S.Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: a single-blinded prospective mono-center study.PLoS One2017;12:e0186720 PMCID:PMC5658076

[95] Song Y,Wang P,Ruan L.CHD is associated with higher grades of NAFLD predicted by liver stiffness.J Clin Gastroenterol2020;54:271-7 PMCID:PMC7012352

[96] Lombardi R,Targher G.Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.Liver Int2020;40:347-54

[97] Mantovani A,Lando MG.Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.Diabetes Metab2020;46:296-303

[98] Mikolasevic I,Turk-Wensween T.Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: a multicenter study.Diabetes Res Clin Pract2021;177:108884

[99] Long MT,Xu H.Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the framingham heart study.Hepatology2021;73:548-59 PMCID:PMC8515503

[100] Pennisi G,Buscemi C.Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.J Gastroenterol Hepatol2021;36:2389-96

[101] Park JG,Verma KK.Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.Aliment Pharmacol Ther2021;53:1030-7

[102] Ciardullo S,Mazzetti S,Perseghin G.Nonalcoholic fatty liver disease, liver fibrosis and cardiovascular disease in the adult US population.Front Endocrinol2021;12:711484 PMCID:PMC8350483

[103] Liu K,Lau K.Prognostic value of controlled attenuation parameter by transient elastography.Am J Gastroenterol2017;112:1812-23

[104] Shili-Masmoudi S,Hiriart JB.Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease.Liver Int2020;40:581-9

[105] Mikolasevic I,Ruzic A.Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus.J Diabetes Complicat2022;36:108226

[106] Cardoso CRL,Leite NC.Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort study.Cardiovasc Diabetol2021;20:193 PMCID:PMC8464106

[107] Grgurevic I,Mustapic S.Liver and nonliver-related outcomes at 2 years are not influenced by the results of the fib-4 test and liver elastography in a real-life cohort of patients with type 2 diabetes.Can J Gastroenterol Hepatol2021;2021:5582813 PMCID:PMC7964120

[108] Petta S,Viganò M.Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease.Clin Gastroenterol Hepatol2021;19:806-815.e5

[109] Mangla N,Caussy C.Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes.Clin Gastroenterol Hepatol2020;18:744-746.e1 PMCID:PMC6984972

[110] Johnson AL,Patel P.Predicting liver-related outcomes in people with nonalcoholic fatty liver disease: the prognostic value of noninvasive fibrosis tests.Hepatol Commun2022;6:728-39 PMCID:PMC8948588

[111] Petta S,Cammà C.Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.Aliment Pharmacol Ther2017;46:617-27

[112] Chan WK,Goh GB.Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis.Clin Gastroenterol Hepatol2019;17:2570-2580.e37

[113] Ballestri S,Nascimbeni F,Lonardo A.Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications.Expert Rev Gastroenterol Hepatol2015;9:603-27

[114] Targher G,Lonardo A,Barbui C.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis.J Hepatol2016;65:589-600

[115] Ballestri S,Nascimbeni F,Lonardo A.Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease.Future Med Chem2019;11:2171-92

[116] Ballestri S,Di Girolamo M.Semi-quantitative ultrasonographic evaluation of NAFLD.Curr Pharm Des2020;26:3915-27

[117] Nascimbeni F,Machado MV.Clinical relevance of liver histopathology and different histological classifications of NASH in adults.Expert Rev Gastroenterol Hepatol2018;12:351-67

[118] Lonardo A,Mantovani A.Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?.J Hepatol2018;68:335-52

[119] Tamaki N,Sharpton SR.Two-step strategy, fib-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD.Clin Gastroenterol Hepatol2022:S1542-3565(22)00077

[120] Lonardo A,Targher G.Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?.Metab Target Organ Damage2021;

[121] Lonardo A.Renaming NAFLD to MAFLD: could the LDE system assist in this transition?.J Clin Med2021;10:492 PMCID:PMC7866816

[122] Lonardo A,Arrese M.Perspectives on precision medicine approaches to nafld diagnosis and management.Adv Ther2021;38:2130-58 PMCID:PMC8107169

[123] Lonardo A.Precision medicine in nonalcoholic fatty liver disease.J Gastroenterol Hepatol2022;37:1175-8

[124] Alkhouri N,Kabler H.Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial.J Hepatol2022;77:607-18

[125] Stokman G,Denker Thorbekk D.Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.Liver Int2020;40:2860-76 PMCID:PMC7702170